MAIA Biotechnology, Inc. (NYSE American ... efficacy data from the Phase 2 THIO-101 clinical trial was accepted for poster presentation at the 2025 Annual Meeting of the American Society of ...

What if business leaders approached strategy the way scientists design gene delivery vectors? In biotechnology, precision, iteration and aligned resources are all critical drivers of breakthroughs ...

and CALGARY, AB, March 9, 2022 /PRNewswire/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced an upcoming poster presentation ... as to the purpose, design, outcomes and ...

IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune modulating cancer vaccines based on its T-win ® technology platform, today announced three poster ...

The second abstract accepted for poster presentation contains new pre-clinical data for the next candidate in the IO Biotech pipeline, IO112, which targets Arginase 1. Times: Poster hall ...

Poster highlights potential predictive biomarker for therapeutic response in advanced non-small cell lung cancer (NSCLC) MAIA Biotechnology, Inc., (NYSE American: MAIA) ("MAIA", the "Company"), a ...

CHICAGO, May 15, 2025--(BUSINESS WIRE)--MAIA Biotechnology ... data from the Phase 2 THIO-101 clinical trial was accepted for poster presentation at the 2025 Annual Meeting of the American ...

CHICAGO--(BUSINESS WIRE)-- MAIA Biotechnology, Inc., (NYSE American ... Updated results” was accepted for poster presentation at the American Society of Clinical Oncology (ASCO) 2024 Annual ...